Bicycle Therapeutics is reducing its headcount by around 25% to extend its cash runway into 2028. | Bicycle Therapeutics is ...

When you think of biotech hubs, the first image that comes to mind may be the sleek waterfront offices of Boston Seaport or ...

As other pharmas drop next-gen obesity assets, Eli Lilly’s experimental oral GLP-1 has prompted weight loss up to ...

Genomics is stepping up to buy Scale Biosciences and its single-cell profiling solutions, with plans to implement them within ...

Longevity company Altos Labs has secured a new clinical leader from the eye of the storm. Former Tornado Therapeutics ...

A group of more than a dozen investors have together purchased a majority stake in HistoSonics, following reports earlier ...

Gilead has returned the rights to a cancer candidate it licensed from Arcus Biosciences in a $725 million, multiprogram deal, ...

After emerging from stealth earlier this year, Apreo Health has raised $130 million to breathe new life into the development ...

Novo Nordisk has abandoned another GLP-1/GIP co-agonist and CB1 receptor as part of a significant pipeline clearout that ...

In its own statement, Edwards said it disagrees with the FTC’s belief that the acquisition will limit access to a new therapy ...

Minghui Pharmaceutical has secured $131 million in what the company describes as a “pre-IPO” round to fuel the potential ...

Lilly paid $47.5 million upfront to license the non-opioid pain drug candidate CNTX-0290 from Centrexion in 2019. The SSTR4 ...